This systematic review and meta-analysis evaluated the safety profile of oral naltrexone by analyzing serious adverse events (SAEs) reported in placebo-controlled randomized controlled trials (RCTs). A total of 89 RCTs involving 11,194 participants across various conditions—including alcohol use disorders, psychiatric disorders, impulse control disorders, obesity, Crohn’s disease, fibromyalgia, and cancer—were
